Shorts

Praful Ravi, MB, BChir, MRCP, highlighted that residual PSMA-avid disease remained detectable on PET imaging in 100% of patients with metastatic HSPC at the 6-month mark.

0:59

PSMAtrack: 100% of mHSPC Group Show Residual PSMA-Avid Disease at 6 Months

2 months ago

Praful Ravi, MB, BChir, MRCP

0:30

How Does Abemaciclib Toxicity Translate from Breast to Gynecologic Cancers?

2 months ago

Jordyn Silverstein, MD

0:49

ADC Vs Standard Chemo Selection in Breast Cancer

2 months ago

Paolo Tarantino, MD, PhD

According to Nicholas Hornstein, MD, PhD, although it broke headlines last year, this year’s presentation for the BREAKWATER trial will be a victory lap.

1:19

What to Expect From the BREAKWATER Trial at ASCO 2026?

2 months ago

Nicholas James Hornstein, MD, PhD

0:55

Personalized Vaccine/Pembrolizumab: The ASCO Abstract to Watch in Glioblastoma

2 months ago

Sonikpreet Aulakh, MBBS, MD

As part of a program conducted at the University of Miami, researchers utilized the Laravel AI platform to identify patient cases and cross-trial comparisons within their platform.

1:11

AI in Cross-Trial Comparison: Optimizing Meta-Analyses in Oncology

2 months ago

Chinmay Jani, MD

0:49

Why are Experts Hopeful About the 2026 ASCO Annual Meeting?

2 months ago

Nicholas James Hornstein, MD, PhD

Nathan Goodyear, MD, discussed exercise as an interventional biologic therapy to supplement standard-of-care anticancer therapies.

1:17

Could Exercise Prime the Immune System for Systemic Anticancer Therapies?

2 months ago

Nathan Goodyear, MD

1:01

Daraxonrasib in 2L PDAC May be the GI Abstract of ASCO 2026

2 months ago

Nicholas James Hornstein, MD, PhD

Mary Steinbach, NP, APRN, highlighted the advantages of subcutaneous isatuximab-irfc delivered via an on-body injector (OBI), which conferred better patient-reported outcomes than the intravenous solution.

0:51

On-Body Injector Brings “Modern” Isatuximab Delivery for Multiple Myeloma

2 months ago

Mary Steinbach, NP, APRN

0:56

Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations

2 months ago

Dana Chase, MD

Following the FDA approval of ruxolitinib extended-release tablets (Jakafi XR) across different myelofibrosis, polycythemia vera, and graft-versus-host disease populations, Naveen Pemmaraju, MD, spoke with CancerNetwork® about what this regulatory decision may mean for hematologic oncology practice.

0:31

How Might Extended-Release Ruxolitinib Tablets Impact Delivery of Care?

2 months ago

Naveen Pemmaraju, MD

Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO, discussed the impact of the Waterless Empirical Taste Test on better identifying and proactively managing oral adverse effects, including dysgeusia, that emerge with talquetamab among patients with multiple myeloma.

0:47

Examining the Impact of the WETT Tool on Talquetamab-Related Oral AEs

2 months ago

Beth Faiman, PhD, MSN, APN-BC

0:55

Prior Interstitial Lung Disease and Ocular Toxicity Pose ADC Treatment Risks

2 months ago

Dana Chase, MD

1:22

Keep 3, Cut 3: Essential Oncology Journals

2 months ago

Balazs Halmos, MD, MS

1:25

The Four Types of Therapy for Second-Line Endometrial Cancer

2 months ago

Dana Chase, MD

1:15

The Ultimate Oncology Conference Bracket

2 months ago

Balazs Halmos, MD, MS

0:43

Expanding the Use of TILs in Metastatic Melanoma Care

2 months ago

Hua-Jay Cherng, MD, discussed how markers such as ctDNA and MRD can translate to actionable strategies for lymphomas.

0:58

Is There Potential for a More Minimally Invasive Alternative to Biopsy?

2 months ago

Hua-Jay J Cherng, MD

Hua-Jay Cherng, MD, discussed how clinicians may be able to get the most out of assessment tools that could be used to inform treatment decision-making processes among lymphoma groups.

1:24

Optimizing the Use of Assessment Tools in Lymphoma Care

2 months ago

Hua-Jay J Cherng, MD

1:00

A Potential Breakthrough With TILs in Metastatic Melanoma

2 months ago

Muhammad Umair Mushtaq, MD

2:15

Blind Ranking Practice-Changing Lung Cancer Trials

2 months ago

Balazs Halmos, MD, MS

Jennifer Effie Amengual, MD, explained how “ancient” endogenous retroviruses can be reactivated by epigenetic therapies to serve as novel targets for immunotherapy in lymphoma.

0:48

Leveraging Ancient Viral Genes to Fight Lymphoma

2 months ago

Jennifer Effie Amengual, MD

Most patients with resectable pancreatic or peripancreatic cancer are candidates for the robotic Whipple surgery, according to Mohamed Adam, MD.

1:12

Who Should Be Selected for Robotic vs Open Pancreaticoduodenectomy?

2 months ago

Mohamed Adam, MD

Hiba Siddiqui, BSc, discussed the mechanism by which engineered macrophage-based immunotherapies would target CD44-expressing bladder cancers.

0:38

Detecting Specific CD44 Types in Bladder Cancer With CAR Macrophage Therapy

2 months ago

Hiba Siddiqui, BSc

1:39

The Mount Rushmore of Oncology

2 months ago

Balazs Halmos, MD, MS

In a conversation with CancerNetwork®, Jonathan Wesley Riess, MD, MS, spoke about efficacy findings from the phase 1/1b RMC-9805-001 study (NCT06040541) that he and colleagues presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

0:52

How Effective Is Zoldonrasib in KRAS G12D+ Non–Small Cell Lung Cancer?

2 months ago

Jonathan Riess, MD, MS

0:57

Life After The Whipple Surgery: Grocery Shopping 7 Days Later

2 months ago

Mohamed Adam, MD

0:56

The Excitement Brewing Around Plixorafenib in BRAF-Altered Cancers

2 months ago

Macarena de la Fuente, MD

After the 2026 National ICE-T Conference in Charlotte, North Carolina, Barry Paul, MD, spoke with CancerNetwork® about key points of discussion in the multiple myeloma paradigm, which included the potential role of fixed-duration therapy with bispecific antibodies.

0:46

Finding a “Sweet Spot” for Fixed-Duration Multiple Myeloma Therapy

2 months ago

Barry Paul, MD

Shorts

Trending on CancerNetwork

Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era

ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?